The House of Representatives has passed 21st Century Cures. Cure SMA is proud to support this legislation. Thank you for your calls and tweets to voice your support to your Representatives. They really made a difference! So what happens next? The Senate is busy drafting their version of the bill, called “Innovation,” and we expect […]
House of Representatives Passes 21st Century Cures Read More »
Each year, while much of our community is gathered together, we use the Annual SMA Conference to recognize several individuals, families and foundations who have provided special support to the Annual SMA Conference and the SMA community. Here are this year’s awardees. On behalf of the entire community, thank you for all you do! Shaina
Seven Individuals and Families Recognized for Their Contributions to the Community Read More »
At last week’s Annual SMA Conference, Cytokinetics released additional data from their Phase 1 study of CK-2127107, a skeletal muscle activator. Cytokinetics, in partnership with Astellas, has already announced that a Phase 2 study will begin later this year. Our partnership with Cytokinetics highlights two strengths of Cure SMA’s research model: providing seed funding to
Cytokinetics Releases Update on Phase 1 Trial at Annual SMA Conference Read More »
At last week’s Annual SMA Conference, Isis Pharmaceuticals, Inc. provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are continuing to receive treatment in an open-label extension (OLE) study. Consistent with earlier observations, increases in muscle function scores and additional motor function
Isis Announces Additional Trial Results at Annual SMA Conference Read More »
Cure SMA has announced plans to fund $1.995 million in new research grants over the next several months. This includes funding for all four areas of our research model—basic research, drug discovery, clinical trials, and clinical care research—plus funding for the 2016 SMA Researcher Meeting, held each year as part of the Annual SMA Conference.
Cure SMA Announces Nearly $2 Million in New Planned Research Funding Read More »
We are very excited to announce that Dr. Mary Schroth has joined us as our medical professional education consultant. She will be working with us a few days each month, depending on her clinic schedule, as Mary remains deeply committed to working with her patients. Mary will also continue to chair our Medical Advisory Council.
Dr. Mary Schroth Joins Cure SMA as Medical Professional Education Consultant Read More »
The latest issue of Compass, our research publication, is now available online. This summer 2015 issue includes information on our recent drug discovery grants, plus an update to our SMA drug pipeline. Developing a treatment and cure for SMA is the driving force behind Cure SMA, and the goal of our three-stage research model. Drug
Read the Summer 2015 Issue of Compass Read More »
The 26th Annual SMA Conference kicks off tomorrow with our Newly Diagnosed Program, and continues into the weekend with all of our usual programs that bring families, researchers, and healthcare providers together to network, learn and —plus a few new initiatives. This will be one of our largest conferences ever. We’re expecting over 1,300 attendees
The 2015 Annual SMA Conference is Here! Read More »
Thank you to the following exhibitors who have generously supported our 2015 Annual SMA Conference. This one-of-a-kind event would not be possible without your support! For more information on any of these companies, please visit our conference exhibitor page. Platinum Ki MobilityQuantum Rehab Gold 3E Love Bio-Rad Laboratories, Inc. Convaid Neotech Products Percussionaire Permobil PromptCare
2015 Annual SMA Conference Exhibitors Read More »
As more and more SMA drug programs progress through clinical trials, there is an increasing need for accurate and unbiased information on clinical trials from our community. Cure SMA has been working to address this through education efforts targeted to the specific needs our community. The centerpiece of these education efforts is our new care
Cure SMA Releases New Clinical Trial Care Series Booklet Read More »
